Developing biomarkers to predict benefit from HGF / MET pathway inhibitors
Hartmut Koeppen, Sandra Rost, Robert L. Yauch · The Journal of Pathology · 2013
Activation of the MET signalling pathway is critical in regulating multiple cellular processes underlying tumourigenic growth and has represented an attractive target for therapeutic intervention in cancer. Early stage clinical studies of multiple agents targeting this pathway have been undertaken, frequently in unselected patient cohorts with variable results. Promising data in patient subgroups in these studies indicate the need for predictive biomarkers to identify the patients most likely to benefit from these therapies. In this review, we discuss the current knowledge of mechanisms of MET activation, the status of the clinical evaluation of MET-targeted therapies, the associated efforts to identify and validate biomarkers, and the considerations and challenges for potential development of companion diagnostics.
Cited by 37 works. doi:10.1002/path.4268 Open-access PDF
Authors
References
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product
- Molecular cloning of a new transforming gene from a chemically transformed human cell line
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- MET signalling: principles and functions in development, organ regeneration and cancer
- Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer
- Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer.